Trial of Covid-19 drug given via inhaler ‘very promising’, say scientists
by Niola Davis/the Guardian
Trials of an experimental drug inhaled by patients have found a significant reduction in hospital patients with Covid-19 needing to be put on a ventilator or dying from the disease, according to researchers
The drug, called SNG001, is delivered via an inhaler and is based on interferon beta, a protein produced naturally in the body that plays an important role in coordinating the body’s antiviral response.
Researchers have announced the results of an initial trial which found the odds of Covid-19 patients needing ventilation, or dying, while being treated in hospital were reduced by 79% among those given SNG001 compared with those given a placebo.
What is more, the team behind the trial say those given the drug were just over twice as likely to show “no limitation of activities” or “no clinical or virological evidence of infection” during the 16-day study period – in other words, the chance of recovery was boosted. Those given the drug also showed a reduction in breathlessness.